The Short Answer
One Pathway or Two
Ozempic® acts on one hormone receptor, GLP-1. Mounjaro® acts on two, GIP and GLP-1, as its label describes it.
Both Are for Type 2 Diabetes
Both labels cover blood sugar control in adults with type 2 diabetes and lowering heart event risk in certain adults with diabetes. Neither label lists weight reduction as an approved use.
A Head-to-Head Trial Exists
The Mounjaro® label includes SURPASS-2, a 40-week trial against semaglutide 1 mg in adults with type 2 diabetes. Average HbA1c and body weight fell more on Mounjaro®, and the details are below.
Stomach Effects Lead Both Lists
Nausea, diarrhea, vomiting and constipation are common on both labels. They tend to show up while the dose is being raised.
Mounjaro® and Ozempic® at a Glance
One row per label fact, from the Mounjaro®, Ozempic® and Ozempic® tablets prescribing information.
| Mounjaro® | Ozempic® | |
|---|---|---|
| Ingredient | Tirzepatide | Semaglutide |
| Maker | Eli Lilly | Novo Nordisk |
| Receptors | GIP and GLP-1 | GLP-1 |
| Approved uses | Type 2 diabetes (adults and children 10+); heart event risk reduction in high-risk adults | Type 2 diabetes in adults; heart and kidney risk reduction in some of those adults |
| Forms | Weekly injection: single-dose pen or vial, multi-dose vial or KwikPen | Weekly injection (pen or prefilled syringe); daily tablet on a separate label |
| Injection sites | Stomach area, thigh; back of the upper arm if someone else injects | Stomach area, thigh, upper arm |
Approved Uses in Full
Mounjaro® is approved for blood sugar control in adults and in children 10 and older with type 2 diabetes. It is also approved to lower major heart event risk in adults with type 2 diabetes who are at high risk for these events.
Ozempic® is approved for blood sugar control in adults with type 2 diabetes. Its label also covers lowering heart event risk in those adults with heart disease and lowering kidney decline risk in those with chronic kidney disease.
Forms and How Often
Both injections are taken once a week at any time of day, with or without meals. Mounjaro® comes in single-dose pens, single-dose vials, multi-dose vials or a multi-dose KwikPen, while Ozempic® injection comes in a multi-dose pen or a single-dose prefilled syringe.
Ozempic® tablets are taken once a day on an empty stomach with up to 4 ounces of water, on a label shared with Rybelsus®. Mounjaro® has no tablet form.
Where the Shot Goes
Both labels list the stomach area and the thigh as injection sites, and both say to rotate sites with each dose. Ozempic® adds the upper arm, and the Mounjaro® label says another person can inject in the back of the upper arm. More in GLP-1 injection sites.
Their Weight-Focused Siblings
Tirzepatide is also sold as Zepbound®, and semaglutide is also sold as Wegovy®, each with its own label for weight reduction. The Wegovy® vs Zepbound® comparison covers those two.
Who Should Not Use Either One
Both labels rule out anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Both also rule out a known serious allergy to the active ingredient or other ingredients.
What the SURPASS-2 Trial Found
SURPASS-2 is the published head-to-head trial, printed in Table 5 of the Mounjaro® label. Every figure is a group average from one open-label trial at 40 weeks.
| Trial arm | Average HbA1c change | Average weight change |
|---|---|---|
| Mounjaro® 5 mg | -2.0 points | -7.6 kg |
| Mounjaro® 10 mg | -2.2 points | -9.3 kg |
| Mounjaro® 15 mg | -2.3 points | -11.2 kg |
| Semaglutide 1 mg | -1.9 points | -5.7 kg |
How the Trial Was Set Up
SURPASS-2 randomized 1,879 adults with type 2 diabetes already taking metformin to Mounjaro® 5 mg, 10 mg or 15 mg, or semaglutide 1 mg, once weekly for 40 weeks. It was open-label and funded by Eli Lilly, and the results are printed in Table 5 of the Mounjaro® label.
HbA1c Results
Average HbA1c fell by 2.0, 2.2 and 2.3 points on the three Mounjaro® doses, compared with 1.9 points on semaglutide 1 mg. The label reports all three Mounjaro® doses (5, 10 and 15 mg) as statistically superior to semaglutide 1 mg for HbA1c.
Body Weight Results
Average weight fell by 7.6 kg, 9.3 kg and 11.2 kg on the three Mounjaro® doses, compared with 5.7 kg on semaglutide 1 mg. These are averages from one trial, not a promise for any one person.
What the Trial Does Not Tell You
The trial compared semaglutide at 1 mg, while the Ozempic® label now goes up to 2 mg. It also studied adults with diabetes only, so the right choice for you still depends on your health and your prescriber.
Dose Steps Listed on Each Label
Quoted from the FDA labels so the numbers make sense. These are each label's own schedule, not a recommendation or a plan for you.
Mounjaro® Steps
The Mounjaro® label starts at 2.5 mg once weekly. If more blood sugar control is needed, it increases in 2.5 mg steps after at least 4 weeks on the current dose, up to 15 mg for adults.
Ozempic® Steps
The Ozempic® injection label starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg. If more control is needed, it lists 1 mg and then 2 mg, each after at least 4 weeks on the step before.
Ozempic® tablets have their own daily ladder of 1.5 mg, 4 mg and 9 mg on a separate label. The tablet label says its tablets are not swapped milligram for milligram with Rybelsus® tablets.
Why the Milligram Numbers Can't Be Compared
Tirzepatide and semaglutide are different molecules, and milligram amounts of different molecules can't be compared. There is no conversion between the two, and your prescriber sets every step.
Common Side Effects on Each Label
Both sets of figures come from placebo-controlled trials in adults with type 2 diabetes. Mounjaro®'s column is the range across its doses; Ozempic®'s shows the two doses studied.
| Side effect | Mounjaro® | Ozempic® |
|---|---|---|
| Nausea | 12-18% vs 4% placebo | 15.8% and 20.3% vs 6.1% placebo |
| Diarrhea | 12-17% vs 9% placebo | 8.5% and 8.8% vs 1.9% placebo |
| Vomiting | 5-9% vs 2% placebo | 5% and 9.2% vs 2.3% placebo |
| Constipation | 6-7% | 5% and 3.1% vs 1.5% placebo |
Other Effects on the Lists
The Mounjaro® label also lists decreased appetite, indigestion and stomach pain among its common effects. The Ozempic® label lists stomach pain and constipation among its most common effects.
Why the Label Tables Differ
Each label's numbers come from its own trials with different people and doses, so read each column against its own placebo rather than against the other.
Full Breakdowns for Each Brand
The GLP-1 side effects guide covers the full tables, why these effects happen and the warning signs to act on.
Keep Either Medicine Organized in Pep AI
After the prescriber decides, daily tracking is what matters.
Quick Logging for Either Shot
Pep AI logs a Mounjaro® or Ozempic® shot in a couple of taps, with its own schedule and step-ups. The body map shows where your recent shots went, so rotating sites gets easier. See the Mounjaro® tracker and the Ozempic® tracker.
Shot-Day Reminders That Fit Your Week
Pep AI reminds you on shot day, and your schedule stays the same week to week unless your prescriber changes it. On iPhone, home-screen widgets, a Lock Screen Live Activity and an Apple Watch app show what is due at a glance.
Symptoms, Day by Day
Pep AI's side-effect log has a built-in list of GLP-1 symptoms, plus your own, each rated for severity on the day you log it. Your dose history keeps its dates too, so you can check which days a step-up came before.
Meals in the Same App
Meals logged by photo scan, barcode, restaurant menu scan or search sit in the same app as your shots, with estimated protein and fiber up front. It becomes easier to see which foods sit well on harder days. More in the GLP-1 food tracker.
Key takeaways
- Mounjaro® (tirzepatide) acts on GIP and GLP-1 receptors; Ozempic® (semaglutide) acts on GLP-1.
- Both are once-weekly injections for adults with type 2 diabetes; neither label lists weight reduction.
- In SURPASS-2, all three Mounjaro® doses lowered average HbA1c more than semaglutide 1 mg, and average weight loss was larger too.
- Milligram amounts of different molecules can't be compared, and there is no conversion between them.
- Which medicine and any switch are your prescriber's decision.
Whatever your prescriber decides, keep the record.
Doses, side effects, meals and weight for any GLP-1 brand, in one app. Pep AI is free to try on iPhone and Android: a free download with a 3-day free trial, then a subscription.
Frequently asked questions
Keep reading
Sources
- Mounjaro® (tirzepatide) prescribing information, Eli Lilly / FDA (revised 08/2026)
- Ozempic® (semaglutide) injection prescribing information, Novo Nordisk / FDA (revised 05/2026)
- Rybelsus® and Ozempic® (semaglutide) tablets prescribing information, Novo Nordisk / FDA (revised 01/2026)
- Zepbound® (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515
This page compares FDA prescribing information and published trials for general information. It is not medical advice and does not tell you which medicine or dose to take; that decision belongs to you and your prescriber. Dose steps are quoted from each label's own schedule, not as a plan for you. Pep AI is not affiliated with Novo Nordisk or Eli Lilly, and brand names are trademarks of their owners. If a symptom is severe or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026